Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Response of patients with refractory myasthenia gravis to rituximab: a retrospective study

Open access
Nowak, Richard J., DiCapua, Daniel B., Zebardast, Nazlee, Goldstein, Jonathan M. · 2011 · Therapeutic Advances in Neurological Disorders

Abstract

Introduction: Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies. A variable response is observed with certain patients being medically refractory. Methods: We report the results of 14 refractory generalized myasthenia gravis patients (6 AChR+; 8 MuSK+) treated with rituximab. Results: Sustained clinical improvement was observed in all patients as well as a reduction of conventional immunotherapies. Prednisone dose decreased a mean of 65.1%, 85.7%, and 93.8% after cycle 1, 2, and 3 of rituximab therapy, respectively. A statistically significant reduction in plasma exchange sessions was seen after cycle 1 with all patients being off of plasma exchange after cycle 3. Acetylcholine receptor antibody titers decreased a mean of 52.1% ( p = 0.0046) post-cycle 2. Conclusion: Our results support the hypothesis that rituximab is beneficial and well tolerated in managing refractory myasthenia gravis and nearly doubles published cases. We propose that B-cell-directed therapies may become an attractive option and suggest pursuit of a prospective trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1756285611411503

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 158

Metadata

Authors
Nowak, R. J., DiCapua, D. B., Zebardast, N., & Goldstein, J. M.
Venue
Therapeutic Advances in Neurological Disorders
Published
2011-07-04
Volume
4
Issue
5
Pages
259-266
ISSN
  • 1756-2856 (ISSN-L)
  • 1756-2864
OpenAlex
W2021398160
Cited by
158
References
1
FWCI
4.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. https://app.cochat.ai/papers/10.1177/1756285611411503
The paper
Nowak, R. J., DiCapua, D. B., Zebardast, N., & Goldstein, J. M. (2011). Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756285611411503

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.